BOCO(SH:600289)2018-10-30 16:00Financial Performance - Revenue for the period was CNY 717,307,428.40, a decline of 17.36% year-on-year[6] - Net profit attributable to shareholders was CNY -458,135,808.53, showing a significant loss compared to CNY -61,240,864.01 in the same period last year[6] - The weighted average return on net assets was -95.54%, a decrease of 93.62 percentage points compared to the previous year[7] - The company reported a net loss of CNY 2.07 billion in retained earnings, compared to a loss of CNY 1.61 billion at the beginning of the year[21] - Net profit for Q3 2018 was a loss of CNY 76,729,651.95, compared to a loss of CNY 86,518,411.56 in Q3 2017, indicating an improvement in performance[29] - The net profit attributable to the parent company for Q3 2018 was -76,637,075.28 CNY, compared to -86,572,720.50 CNY in the same period last year, indicating an improvement of approximately 11.2%[30] - The total comprehensive income attributable to the parent company for Q3 2018 was -76,729,651.95 CNY, showing a decrease from -86,518,411.56 CNY year-over-year[30] Cash Flow - The net cash flow from operating activities was CNY -177,893,216.17, an improvement from CNY -539,148,171.31 year-on-year[6] - The net cash flow from financing activities was CNY -20,050,508.33, a decrease from CNY -400,154,291.78 year-on-year[12] - Operating cash inflow for the first nine months of 2018 was CNY 888,909,404.05, a slight decrease from CNY 905,256,234.11 in the same period last year[40] - Net cash flow from operating activities was CNY 11,926,652.43, a significant improvement compared to a net outflow of CNY -733,431,104.51 in the previous year[40] - Total cash outflow from operating activities reached CNY 876,982,751.62, down from CNY 1,638,687,338.62 year-on-year[40] - Cash inflow from financing activities was CNY 50,000,000.00, primarily from loans, while cash outflow was CNY 20,050,508.33[37] Assets and Liabilities - Total assets decreased by 9.13% to CNY 2,709,935,833.28 compared to the end of the previous year[6] - The company's total liabilities increased to CNY 2.46 billion from CNY 2.28 billion at the beginning of the year, indicating worsening financial health[21] - The company's equity attributable to shareholders decreased significantly to CNY 250.4 million from CNY 708.6 million at the beginning of the year, reflecting substantial losses[21] - Total assets as of September 30, 2018, amounted to CNY 4,242,157,379.84, up from CNY 4,107,224,130.92 at the beginning of the year, reflecting a growth of 3.3%[24] - Total liabilities increased to CNY 2,557,857,433.72 from CNY 2,282,830,082.44, representing a rise of 12.0%[25] - The company’s total equity decreased to CNY 1,684,299,946.12 from CNY 1,824,394,048.48, reflecting a decline of 7.7%[25] Legal and Regulatory Issues - The company faced multiple legal lawsuits affecting its operations and new contract signings, leading to a decline in employee morale and efficiency[12] - The company is under investigation by the China Securities Regulatory Commission for alleged violations of securities laws, and is actively cooperating with the investigation[13] - The company has initiated legal action against the controlling shareholder to protect the interests of the company and minority shareholders, with the controlling shareholder promising to repay the deducted funds[15] - The company faced a court-ordered deduction of funds amounting to CNY 48.8 million due to a lawsuit, resulting in an additional expense of CNY 25.8 million in the current period[13] Shareholder Information - The number of shareholders at the end of the reporting period was 44,760[9] - The top shareholder, Yiyang Group Co., Ltd., held 32.89% of the shares, with 207,573,483 shares frozen[9] Research and Development - Research and development expenses for the first nine months of 2018 were CNY 15,109,885.32, up from CNY 11,912,356.68 in the same period last year, indicating a focus on innovation[29] Other Financial Metrics - The company recognized an estimated compensation of CNY 232 million related to litigation, significantly impacting the current period's profit[12] - The company confirmed a receivable of CNY 477 million from Beijing Wuzhou Botong Technology Co., which is under special review, and the controlling shareholder has acknowledged borrowing funds from the company[14] - The company plans to evaluate a stem cell project as collateral for the repayment of the CNY 477 million owed by the controlling shareholder[14]